Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Olopatadine Hydrochloride; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• 12 years of age or older.

• History (within the past 24 months) of allergic conjunctivitis.

• Active signs and symptoms of ocular allergies.

• Ocular health within normal limits, as determined by the investigator or subinvestigator.

• Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Contraindications or hypersensitivity to study medication or its components.

• One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit.

• Known history of recurrent corneal erosion syndrome.

• Ocular trauma or surgical intervention within 6 months prior to Visit 1.

• Participation in any other investigational study within 30 days before Visit 1.

• Pregnant or nursing.

• Other protocol-defined exclusion criteria may apply.